Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights

-IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1 million as of Q2 2022- CARLSBAD, Calif., Aug. 4, 2022 /PRNewswire/ — Tyra Biosciences, Inc….

Click here to view original post